Academic Journal
View in EDS

Impact of Cipepofol versus Propofol on Long-Term Cardiovascular Outcomes After TAVR: An Extended Follow-Up of a Randomized Trial.

Bibliographic Details
Title: Impact of Cipepofol versus Propofol on Long-Term Cardiovascular Outcomes After TAVR: An Extended Follow-Up of a Randomized Trial.
Authors: Ni T; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Lv Y; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Zhou L; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Yu J; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Tao X; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Cao H; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Yao Y; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Yan M; Department of Anesthesiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Source: Drug design, development and therapy [Drug Des Devel Ther] 2026 Sep 17; Vol. 20, pp. 621481. Date of Electronic Publication: 2026 Sep 17 (Print Publication: 2026).
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study
Language: English
Journal Info: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE
Imprint Name(s): Original Publication: [Auckland, N.Z.] : Dove Press Limited
MeSH Terms: Propofol*/administration & dosage , Propofol*/adverse effects , Anesthetics, Intravenous*/administration & dosage , Transcatheter Aortic Valve Replacement*, Humans ; Female ; Follow-Up Studies ; Male ; Aged, 80 and over ; Aged ; Treatment Outcome ; Time Factors
Abstract: Background: Patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) under general anesthesia are particularly vulnerable to hemodynamic instability. General anesthesia remains a common approach and is necessary in selected patients, although conscious sedation is increasingly used. A previous randomized trial showed greater peri-induction hemodynamic stability with cipepofol than with propofol, but whether this translates into improved clinical outcomes is uncertain.
Methods: We conducted a post hoc, exploratory extended follow-up of a single-center randomized trial. Patients were randomly assigned to cipepofol or propofol. In-hospital analyses included 122 TAVR-treated participants (61 per group), whereas the 30-day and 1-year analyses included 118 participants with follow-up data in the full analysis set (59 per group). The primary endpoint was the 1-year composite of all-cause mortality, stroke, acute kidney injury, myocardial infarction, and new-onset atrial fibrillation (NOAF). For this exploratory analysis, the components were grouped based on their hypothesized association with periprocedural hemodynamic instability and were also reported separately.
Results: At 1 year, the primary composite endpoint occurred in 13/59 (22.0%) patients in the cipepofol group and 22/59 (37.3%) patients in the propofol group (hazard ratio [HR] 0.56; 95% confidence interval [CI] 0.28 to 1.10; P = 0.093). NOAF, analyzed separately as an exploratory secondary endpoint, occurred less frequently with cipepofol than with propofol (7/59 [11.9%] vs 17/59 [28.8%]; HR 0.39; 95% CI 0.16 to 0.95; P = 0.037). At 30 days, the composite endpoint occurred in 9/59 (15.3%) and 14/59 (23.7%) patients, respectively (HR 0.63; 95% CI 0.27 to 1.45; P = 0.277). The in-hospital composite endpoints were 10/61 (16.4%) and 16/61 (26.2%), respectively (P = 0.185).
Conclusion: In this exploratory extended follow-up, cipepofol did not significantly reduce the 1-year primary composite endpoint compared with propofol. The observed lower incidence of NOAF should be regarded as hypothesis-generating given the limited sample size, multiple comparisons, and intermittent rhythm surveillance. The applicability of these findings is limited to patients undergoing transfemoral TAVR under general anesthesia and does not extend to procedures performed under conscious sedation.
(© 2026 Ni et al.)
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References: JACC Cardiovasc Interv. 2022 Mar 28;15(6):603-613. (PMID: 35331452)
JACC Cardiovasc Interv. 2023 Nov 13;16(21):2631-2641. (PMID: 37737793)
Anesthesiology. 2017 Jan;126(1):47-65. (PMID: 27792044)
JACC Cardiovasc Interv. 2020 Jun 8;13(11):1277-1287. (PMID: 32499018)
Heart Rhythm O2. 2025 Jan 10;6(3):273-279. (PMID: 40201675)
J Am Coll Cardiol. 2021 May 4;77(17):2204-2215. (PMID: 33926657)
JACC Cardiovasc Interv. 2019 Nov 11;12(21):2119-2129. (PMID: 31629743)
Eur Heart J. 2023 Mar 21;44(12):1020-1039. (PMID: 36721960)
Intensive Care Med. 2018 Jun;44(6):811-822. (PMID: 29868971)
Anesthesiology. 2022 Jun 1;136(6):927-939. (PMID: 35188970)
Int J Cardiol. 2022 Oct 15;365:44-46. (PMID: 35863494)
J Clin Anesth. 2024 Jun;94:111425. (PMID: 38412619)
Circulation. 2025 Apr 22;151(16):1134-1146. (PMID: 40177743)
Ann Intern Med. 2013 Jun 4;158(11):825-30. (PMID: 23732715)
JAMA. 2017 Oct 10;318(14):1346-1357. (PMID: 28973220)
J Med Chem. 2017 May 11;60(9):3606-3617. (PMID: 28430430)
JAMA Surg. 2025 Jul 1;160(7):763-770. (PMID: 40397427)
Nat Rev Cardiol. 2019 Jul;16(7):417-436. (PMID: 30792496)
Circulation. 2021 Feb 2;143(5):e72-e227. (PMID: 33332150)
JAMA. 2018 May 8;319(18):1889-1900. (PMID: 29801010)
J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746. (PMID: 33888385)
Circulation. 2020 Oct 13;142(15):1437-1447. (PMID: 32819145)
Life (Basel). 2022 Dec 10;12(12):. (PMID: 36556439)
J Am Coll Cardiol. 2025 Jan 7;85(1):74-82. (PMID: 39503651)
J Cardiothorac Vasc Anesth. 2012 Aug;26(4):733-5. (PMID: 22503345)
JAMA Cardiol. 2021 Sep 1;6(9):1088-1089. (PMID: 34287627)
Eur Heart J. 2025 Nov 21;46(44):4635-4736. (PMID: 40878295)
Int J Clin Pract. 2019 Oct;73(10):e13394. (PMID: 31332896)
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1746-1756. (PMID: 30190063)
Contributed Indexing: Keywords: cipepofol; general anesthesia; hemodynamic stability; new-onset atrial fibrillation; propofol; transcatheter aortic valve replacement
Substance Nomenclature: YI7VU623SF (Propofol)
0 (Anesthetics, Intravenous)
Entry Date(s): Date Created: 20260923 Date Completed: 20260923 Latest Revision: 20261016
Update Code: 20261016
PubMed Central ID: PMC13594509
DOI: 10.2147/DDDT.S621481
PMID: 42774398
Database: MEDLINE
Description
ISSN:1177-8881
DOI:10.2147/DDDT.S621481